Rahul Nahar
Overview
Explore the profile of Rahul Nahar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joanito I, Wirapati P, Zhao N, Nawaz Z, Yeo G, Lee F, et al.
Nat Genet
. 2022 Jun;
54(7):963-975.
PMID: 35773407
The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed 373,058 single-cell transcriptomes from 63 patients, focusing...
2.
Chua K, Teng Y, Tan A, Takano A, Alvarez J, Nahar R, et al.
Clin Cancer Res
. 2021 Jul;
27(21):5939-5950.
PMID: 34261696
Purpose: Despite the established role of EGFR tyrosine kinase inhibitors (TKIs) in -mutated NSCLC, drug resistance inevitably ensues, with a paucity of treatment options especially in -negative resistance. Experimental Design:...
3.
Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C, et al.
Nat Genet
. 2020 Feb;
52(2):177-186.
PMID: 32015526
Lung cancer is the world's leading cause of cancer death and shows strong ancestry disparities. By sequencing and assembling a large genomic and transcriptomic dataset of lung adenocarcinoma (LUAD) in...
4.
Lai G, Lim T, Lim J, Liew P, Kwang X, Nahar R, et al.
J Clin Oncol
. 2019 Jan;
37(11):876-884.
PMID: 30676858
Purpose: Mesenchymal epithelial transition factor ( MET) activation has been implicated as an oncogenic driver in epidermal growth factor receptor ( EGFR)-mutant non-small-cell lung cancer (NSCLC) and can mediate primary...
5.
Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K, et al.
Nature
. 2018 May;
557(7706):575-579.
PMID: 29769722
Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving to be effective at restoring T cell-mediated immune responses that can lead to marked and sustained clinical responses, but...
6.
Nahar R, Zhai W, Zhang T, Takano A, Khng A, Lee Y, et al.
Nat Commun
. 2018 Jan;
9(1):216.
PMID: 29335443
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized by rapid but short-lived responses to EGFR tyrosine kinase inhibitors (TKIs). Through sequencing of 79 spatially distinct regions from...
7.
Geng H, Hurtz C, Lenz K, Chen Z, Baumjohann D, Thompson S, et al.
Cancer Cell
. 2015 Mar;
27(3):409-25.
PMID: 25759025
Studying 830 pre-B ALL cases from four clinical trials, we found that human ALL can be divided into two fundamentally distinct subtypes based on pre-BCR function. While absent in the...
8.
Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, et al.
Blood
. 2011 Aug;
118(15):4174-8.
PMID: 21856866
Initial cell surface expression of the pre-B cell receptor induces proliferation. After 2 to 5 divisions, however, large pre-BII (Fraction C') cells exit cell cycle to become resting, small pre-BII...
9.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al.
Nature
. 2011 May;
473(7347):384-8.
PMID: 21593872
Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent...
10.
Duy C, Yu J, Nahar R, Swaminathan S, Kweon S, Polo J, et al.
J Exp Med
. 2010 May;
207(6):1209-21.
PMID: 20498019
BCL6 protects germinal center (GC) B cells against DNA damage-induced apoptosis during somatic hypermutation and class-switch recombination. Although expression of BCL6 was not found in early IL-7-dependent B cell precursors,...